Entecavir  ||| S:0 E:10 ||| NNP
for  ||| S:10 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
treatment  ||| S:18 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
chronic  ||| S:31 E:39 ||| JJ
hepatitis  ||| S:39 E:49 ||| NNP
B  ||| S:49 E:51 ||| NNP
infection  ||| S:51 E:61 ||| VBD
This  ||| S:61 E:66 ||| DT
paper  ||| S:66 E:72 ||| NN
presents  ||| S:72 E:81 ||| VBZ
a  ||| S:81 E:83 ||| DT
summary  ||| S:83 E:91 ||| NN
of  ||| S:91 E:94 ||| IN
the  ||| S:94 E:98 ||| DT
evidence  ||| S:98 E:107 ||| NN
review  ||| S:107 E:114 ||| NN
group  ||| S:114 E:120 ||| NN
( ||| S:120 E:121 ||| -LRB-
ERG ||| S:121 E:124 ||| NNP
)  ||| S:124 E:126 ||| -RRB-
report  ||| S:126 E:133 ||| NN
into  ||| S:133 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
clinical  ||| S:142 E:151 ||| JJ
and  ||| S:151 E:155 ||| CC
cost-effectiveness  ||| S:155 E:174 ||| JJ
of  ||| S:174 E:177 ||| IN
entecavir  ||| S:177 E:187 ||| NN
for  ||| S:187 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
treatment  ||| S:195 E:205 ||| NN
of  ||| S:205 E:208 ||| IN
chronic  ||| S:208 E:216 ||| JJ
hepatitis  ||| S:216 E:226 ||| NNP
B  ||| S:226 E:228 ||| NNP
( ||| S:228 E:229 ||| -LRB-
CHB ||| S:229 E:232 ||| NNP
)  ||| S:232 E:234 ||| -RRB-
in  ||| S:234 E:237 ||| IN
adults  ||| S:237 E:244 ||| NNS
based  ||| S:244 E:250 ||| VBN
upon  ||| S:250 E:255 ||| IN
a  ||| S:255 E:257 ||| DT
review  ||| S:257 E:264 ||| NN
of  ||| S:264 E:267 ||| IN
the  ||| S:267 E:271 ||| DT
manufacturer ||| S:271 E:283 ||| NN
's  ||| S:283 E:286 ||| POS
submission  ||| S:286 E:297 ||| NN
to  ||| S:297 E:300 ||| TO
the  ||| S:300 E:304 ||| DT
National  ||| S:304 E:313 ||| NNP
Institute  ||| S:313 E:323 ||| NNP
for  ||| S:323 E:327 ||| IN
Health  ||| S:327 E:334 ||| NNP
and  ||| S:334 E:338 ||| CC
Clinical  ||| S:338 E:347 ||| NNP
Excellence  ||| S:347 E:358 ||| NNP
( ||| S:358 E:359 ||| -LRB-
NICE ||| S:359 E:363 ||| NNP
)  ||| S:363 E:365 ||| -RRB-
as  ||| S:365 E:368 ||| IN
part  ||| S:368 E:373 ||| NN
of  ||| S:373 E:376 ||| IN
the  ||| S:376 E:380 ||| DT
single  ||| S:380 E:387 ||| JJ
technology  ||| S:387 E:398 ||| NN
appraisal  ||| S:398 E:408 ||| NN
( ||| S:408 E:409 ||| -LRB-
STA ||| S:409 E:412 ||| NNP
)  ||| S:412 E:414 ||| -RRB-
process ||| S:414 E:421 ||| NN
.  ||| S:421 E:423 ||| .
The  ||| S:423 E:427 ||| DT
submission ||| S:427 E:437 ||| NN
's  ||| S:437 E:440 ||| POS
evidence  ||| S:440 E:449 ||| NN
came  ||| S:449 E:454 ||| VBD
from  ||| S:454 E:459 ||| IN
five  ||| S:459 E:464 ||| CD
randomised  ||| S:464 E:475 ||| NNS
controlled  ||| S:475 E:486 ||| VBN
trials  ||| S:486 E:493 ||| NNS
( ||| S:493 E:494 ||| -LRB-
RCTs ||| S:494 E:498 ||| NNP
) ||| S:498 E:499 ||| -RRB-
,  ||| S:499 E:501 ||| ,
of  ||| S:501 E:504 ||| IN
good  ||| S:504 E:509 ||| JJ
methodological  ||| S:509 E:524 ||| JJ
quality  ||| S:524 E:532 ||| NN
and  ||| S:532 E:536 ||| CC
measuring  ||| S:536 E:546 ||| VBG
a  ||| S:546 E:548 ||| DT
range  ||| S:548 E:554 ||| NN
of  ||| S:554 E:557 ||| IN
clinically  ||| S:557 E:568 ||| JJ
relevant  ||| S:568 E:577 ||| JJ
outcomes ||| S:577 E:585 ||| NNS
,  ||| S:585 E:587 ||| ,
comparing  ||| S:587 E:597 ||| VBG
entecavir  ||| S:597 E:607 ||| NN
with  ||| S:607 E:612 ||| IN
lamivudine ||| S:612 E:622 ||| NN
.  ||| S:622 E:624 ||| .
After  ||| S:624 E:630 ||| IN
1  ||| S:630 E:632 ||| CD
year  ||| S:632 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
treatment  ||| S:640 E:650 ||| NN
entecavir  ||| S:650 E:660 ||| NNS
was  ||| S:660 E:664 ||| VBD
statistically  ||| S:664 E:678 ||| RB
superior  ||| S:678 E:687 ||| JJ
to  ||| S:687 E:690 ||| TO
lamivudine  ||| S:690 E:701 ||| VB
in  ||| S:701 E:704 ||| IN
terms  ||| S:704 E:710 ||| NNS
of  ||| S:710 E:713 ||| IN
the  ||| S:713 E:717 ||| DT
proportion  ||| S:717 E:728 ||| NN
of  ||| S:728 E:731 ||| IN
patients  ||| S:731 E:740 ||| NNS
achieving  ||| S:740 E:750 ||| VBG
hepatitis  ||| S:750 E:760 ||| NNP
B  ||| S:760 E:762 ||| NNP
virus  ||| S:762 E:768 ||| NN
( ||| S:768 E:769 ||| -LRB-
HBV ||| S:769 E:772 ||| NNP
)  ||| S:772 E:774 ||| -RRB-
DNA  ||| S:774 E:778 ||| NNP
suppression ||| S:778 E:789 ||| NN
,  ||| S:789 E:791 ||| ,
alanine  ||| S:791 E:799 ||| FW
aminotransferase  ||| S:799 E:816 ||| FW
( ||| S:816 E:817 ||| -LRB-
ALT ||| S:817 E:820 ||| NNP
)  ||| S:820 E:822 ||| -RRB-
normalisation  ||| S:822 E:836 ||| NN
and  ||| S:836 E:840 ||| CC
histological  ||| S:840 E:853 ||| JJ
improvement ||| S:853 E:864 ||| NN
,  ||| S:864 E:866 ||| ,
but  ||| S:866 E:870 ||| CC
not  ||| S:870 E:874 ||| RB
in  ||| S:874 E:877 ||| IN
terms  ||| S:877 E:883 ||| NNS
of  ||| S:883 E:886 ||| IN
the  ||| S:886 E:890 ||| DT
proportion  ||| S:890 E:901 ||| NN
of  ||| S:901 E:904 ||| IN
patients  ||| S:904 E:913 ||| NNS
achieving  ||| S:913 E:923 ||| VBG
hepatitis  ||| S:923 E:933 ||| NNP
B  ||| S:933 E:935 ||| NNP
e  ||| S:935 E:937 ||| SYM
antigen  ||| S:937 E:945 ||| FW
( ||| S:945 E:946 ||| -LRB-
HBeAg ||| S:946 E:951 ||| NNP
)  ||| S:951 E:953 ||| -RRB-
seroconversion ||| S:953 E:967 ||| NN
.  ||| S:967 E:969 ||| .
The  ||| S:969 E:973 ||| DT
incidence  ||| S:973 E:983 ||| NN
of  ||| S:983 E:986 ||| IN
adverse  ||| S:986 E:994 ||| JJ
or  ||| S:994 E:997 ||| CC
serious  ||| S:997 E:1005 ||| JJ
adverse  ||| S:1005 E:1013 ||| JJ
events  ||| S:1013 E:1020 ||| NNS
was  ||| S:1020 E:1024 ||| VBD
similar  ||| S:1024 E:1032 ||| JJ
for  ||| S:1032 E:1036 ||| IN
both  ||| S:1036 E:1041 ||| DT
treatments ||| S:1041 E:1051 ||| NNS
.  ||| S:1051 E:1053 ||| .
The  ||| S:1053 E:1057 ||| DT
results  ||| S:1057 E:1065 ||| NNS
of  ||| S:1065 E:1068 ||| IN
the  ||| S:1068 E:1072 ||| DT
manufacturer ||| S:1072 E:1084 ||| NN
's  ||| S:1084 E:1087 ||| POS
mixed  ||| S:1087 E:1093 ||| JJ
treatment  ||| S:1093 E:1103 ||| NN
comparison  ||| S:1103 E:1114 ||| NN
( ||| S:1114 E:1115 ||| -LRB-
MTC ||| S:1115 E:1118 ||| NNP
)  ||| S:1118 E:1120 ||| -RRB-
model  ||| S:1120 E:1126 ||| NN
to  ||| S:1126 E:1129 ||| TO
compare  ||| S:1129 E:1137 ||| VB
entecavir  ||| S:1137 E:1147 ||| VBN
with  ||| S:1147 E:1152 ||| IN
the  ||| S:1152 E:1156 ||| DT
comparator  ||| S:1156 E:1167 ||| JJ
drugs  ||| S:1167 E:1173 ||| NNS
in  ||| S:1173 E:1176 ||| IN
nucleoside-naive  ||| S:1176 E:1193 ||| JJ
patients  ||| S:1193 E:1202 ||| NNS
were  ||| S:1202 E:1207 ||| VBD
considered  ||| S:1207 E:1218 ||| VBN
to  ||| S:1218 E:1221 ||| TO
be  ||| S:1221 E:1224 ||| VB
uncertain  ||| S:1224 E:1234 ||| JJ
because  ||| S:1234 E:1242 ||| IN
of  ||| S:1242 E:1245 ||| IN
concerns  ||| S:1245 E:1254 ||| NNS
over  ||| S:1254 E:1259 ||| IN
its  ||| S:1259 E:1263 ||| PRP$
conduct  ||| S:1263 E:1271 ||| NN
and  ||| S:1271 E:1275 ||| CC
reporting ||| S:1275 E:1284 ||| NN
.  ||| S:1284 E:1286 ||| .
For  ||| S:1286 E:1290 ||| IN
the  ||| S:1290 E:1294 ||| DT
economic  ||| S:1294 E:1303 ||| JJ
evaluation  ||| S:1303 E:1314 ||| NN
the  ||| S:1314 E:1318 ||| DT
manufacturer  ||| S:1318 E:1331 ||| NN
constructed  ||| S:1331 E:1343 ||| VBN
two  ||| S:1343 E:1347 ||| CD
Markov  ||| S:1347 E:1354 ||| JJ
state  ||| S:1354 E:1360 ||| NN
transition  ||| S:1360 E:1371 ||| NN
models ||| S:1371 E:1377 ||| NNS
,  ||| S:1377 E:1379 ||| ,
one  ||| S:1379 E:1383 ||| CD
in  ||| S:1383 E:1386 ||| IN
HBeAg-positive  ||| S:1386 E:1401 ||| JJ
and  ||| S:1401 E:1405 ||| CC
one  ||| S:1405 E:1409 ||| CD
in  ||| S:1409 E:1412 ||| IN
HBeAg-negative  ||| S:1412 E:1427 ||| JJ
patients ||| S:1427 E:1435 ||| NNS
.  ||| S:1435 E:1437 ||| .
The  ||| S:1437 E:1441 ||| DT
modelling  ||| S:1441 E:1451 ||| JJ
approach  ||| S:1451 E:1460 ||| NN
was  ||| S:1460 E:1464 ||| VBD
considered  ||| S:1464 E:1475 ||| VBN
reasonable  ||| S:1475 E:1486 ||| JJ
subject  ||| S:1486 E:1494 ||| NN
to  ||| S:1494 E:1497 ||| TO
some  ||| S:1497 E:1502 ||| DT
uncertainties  ||| S:1502 E:1516 ||| NNS
and  ||| S:1516 E:1520 ||| CC
concerns  ||| S:1520 E:1529 ||| NNS
over  ||| S:1529 E:1534 ||| IN
some  ||| S:1534 E:1539 ||| DT
of  ||| S:1539 E:1542 ||| IN
the  ||| S:1542 E:1546 ||| DT
structural  ||| S:1546 E:1557 ||| JJ
assumptions ||| S:1557 E:1568 ||| NNS
.  ||| S:1568 E:1570 ||| .
In  ||| S:1570 E:1573 ||| IN
HBeAg-positive  ||| S:1573 E:1588 ||| JJ
patients  ||| S:1588 E:1597 ||| NNS
the  ||| S:1597 E:1601 ||| DT
base-case  ||| S:1601 E:1611 ||| JJ
incremental  ||| S:1611 E:1623 ||| JJ
cost-effectiveness  ||| S:1623 E:1642 ||| JJ
ratios  ||| S:1642 E:1649 ||| NNS
( ||| S:1649 E:1650 ||| -LRB-
ICER ||| S:1650 E:1654 ||| NNP
)  ||| S:1654 E:1656 ||| -RRB-
for  ||| S:1656 E:1660 ||| IN
entecavir  ||| S:1660 E:1670 ||| VBG
compared  ||| S:1670 E:1679 ||| VBN
with  ||| S:1679 E:1684 ||| IN
lamivudine  ||| S:1684 E:1695 ||| NN
and  ||| S:1695 E:1699 ||| CC
pegylated  ||| S:1699 E:1709 ||| JJ
interferon  ||| S:1709 E:1720 ||| JJ
alpha-2a  ||| S:1720 E:1729 ||| NN
were  ||| S:1729 E:1734 ||| VBD
14,329  ||| S:1734 E:1741 ||| CD
pounds  ||| S:1741 E:1748 ||| NNS
and  ||| S:1748 E:1752 ||| CC
8403  ||| S:1752 E:1757 ||| CD
pounds  ||| S:1757 E:1764 ||| NNS
per  ||| S:1764 E:1768 ||| IN
quality-adjusted  ||| S:1768 E:1785 ||| JJ
life-year  ||| S:1785 E:1795 ||| NN
( ||| S:1795 E:1796 ||| -LRB-
QALY ||| S:1796 E:1800 ||| NNP
)  ||| S:1800 E:1802 ||| -RRB-
respectively ||| S:1802 E:1814 ||| RB
.  ||| S:1814 E:1816 ||| .
Entecavir  ||| S:1816 E:1826 ||| NNP
was  ||| S:1826 E:1830 ||| VBD
dominated  ||| S:1830 E:1840 ||| VBN
by  ||| S:1840 E:1843 ||| IN
telbivudine ||| S:1843 E:1854 ||| NN
.  ||| S:1854 E:1856 ||| .
In  ||| S:1856 E:1859 ||| IN
HBeAg-negative  ||| S:1859 E:1874 ||| JJ
patients  ||| S:1874 E:1883 ||| NNS
the  ||| S:1883 E:1887 ||| DT
base-case  ||| S:1887 E:1897 ||| JJ
ICERs  ||| S:1897 E:1903 ||| NN
for  ||| S:1903 E:1907 ||| IN
entecavir  ||| S:1907 E:1917 ||| VBG
compared  ||| S:1917 E:1926 ||| VBN
with  ||| S:1926 E:1931 ||| IN
lamivudine ||| S:1931 E:1941 ||| NN
,  ||| S:1941 E:1943 ||| ,
pegylated  ||| S:1943 E:1953 ||| FW
interferon  ||| S:1953 E:1964 ||| FW
alpha-2a  ||| S:1964 E:1973 ||| FW
and  ||| S:1973 E:1977 ||| CC
telbivudine  ||| S:1977 E:1989 ||| NNS
were  ||| S:1989 E:1994 ||| VBD
13,208  ||| S:1994 E:2001 ||| CD
pounds ||| S:2001 E:2007 ||| NNS
,  ||| S:2007 E:2009 ||| ,
7511  ||| S:2009 E:2014 ||| CD
pounds  ||| S:2014 E:2021 ||| NNS
and  ||| S:2021 E:2025 ||| CC
6907  ||| S:2025 E:2030 ||| CD
pounds  ||| S:2030 E:2037 ||| NNS
per  ||| S:2037 E:2041 ||| IN
QALY  ||| S:2041 E:2046 ||| NNP
respectively ||| S:2046 E:2058 ||| RB
.  ||| S:2058 E:2060 ||| .
In  ||| S:2060 E:2063 ||| IN
HBeAg-positive  ||| S:2063 E:2078 ||| JJ
lamivudine-refractory  ||| S:2078 E:2100 ||| JJ
patients  ||| S:2100 E:2109 ||| NNS
entecavir  ||| S:2109 E:2119 ||| VBP
dominated  ||| S:2119 E:2129 ||| VBN
adefovir  ||| S:2129 E:2138 ||| NNS
added  ||| S:2138 E:2144 ||| VBD
to  ||| S:2144 E:2147 ||| TO
lamivudine ||| S:2147 E:2157 ||| VB
.  ||| S:2157 E:2159 ||| .
In  ||| S:2159 E:2162 ||| IN
one-way  ||| S:2162 E:2170 ||| JJ
deterministic  ||| S:2170 E:2184 ||| JJ
sensitivity  ||| S:2184 E:2196 ||| NN
analysis  ||| S:2196 E:2205 ||| NN
on  ||| S:2205 E:2208 ||| IN
all  ||| S:2208 E:2212 ||| DT
key  ||| S:2212 E:2216 ||| JJ
input  ||| S:2216 E:2222 ||| NN
parameters  ||| S:2222 E:2233 ||| NNS
for  ||| S:2233 E:2237 ||| IN
entecavir  ||| S:2237 E:2247 ||| VBG
compared  ||| S:2247 E:2256 ||| VBN
with  ||| S:2256 E:2261 ||| IN
lamivudine  ||| S:2261 E:2272 ||| NN
in  ||| S:2272 E:2275 ||| IN
nucleoside-naive  ||| S:2275 E:2292 ||| JJ
patients ||| S:2292 E:2300 ||| NNS
,  ||| S:2300 E:2302 ||| ,
ICERs  ||| S:2302 E:2308 ||| NNP
generally  ||| S:2308 E:2318 ||| RB
remained  ||| S:2318 E:2327 ||| VBN
under  ||| S:2327 E:2333 ||| IN
30,000  ||| S:2333 E:2340 ||| CD
pounds  ||| S:2340 E:2347 ||| NNS
per  ||| S:2347 E:2351 ||| IN
QALY ||| S:2351 E:2355 ||| NNP
.  ||| S:2355 E:2357 ||| .
In  ||| S:2357 E:2360 ||| IN
probabilistic  ||| S:2360 E:2374 ||| JJ
sensitivity  ||| S:2374 E:2386 ||| NN
analysis  ||| S:2386 E:2395 ||| NN
in  ||| S:2395 E:2398 ||| IN
nucleoside-naive  ||| S:2398 E:2415 ||| JJ
HBeAg-positive  ||| S:2415 E:2430 ||| JJ
patients  ||| S:2430 E:2439 ||| NNS
the  ||| S:2439 E:2443 ||| DT
probability  ||| S:2443 E:2455 ||| NN
of  ||| S:2455 E:2458 ||| IN
the  ||| S:2458 E:2462 ||| DT
ICER  ||| S:2462 E:2467 ||| NNP
for  ||| S:2467 E:2471 ||| IN
entecavir  ||| S:2471 E:2481 ||| NNS
being  ||| S:2481 E:2487 ||| VBG
below  ||| S:2487 E:2493 ||| IN
20,000  ||| S:2493 E:2500 ||| CD
pounds  ||| S:2500 E:2507 ||| NNS
per  ||| S:2507 E:2511 ||| IN
QALY  ||| S:2511 E:2516 ||| NNP
was  ||| S:2516 E:2520 ||| VBD
57 ||| S:2520 E:2522 ||| CD
% ||| S:2522 E:2523 ||| NN
,  ||| S:2523 E:2525 ||| ,
82 ||| S:2525 E:2527 ||| CD
%  ||| S:2527 E:2529 ||| NN
and  ||| S:2529 E:2533 ||| CC
45 ||| S:2533 E:2535 ||| CD
%  ||| S:2535 E:2537 ||| NN
compared  ||| S:2537 E:2546 ||| VBN
with  ||| S:2546 E:2551 ||| IN
lamivudine ||| S:2551 E:2561 ||| NN
,  ||| S:2561 E:2563 ||| ,
pegylated  ||| S:2563 E:2573 ||| FW
interferon  ||| S:2573 E:2584 ||| FW
alpha-2a  ||| S:2584 E:2593 ||| FW
and  ||| S:2593 E:2597 ||| CC
telbivudine  ||| S:2597 E:2609 ||| VBP
respectively ||| S:2609 E:2621 ||| RB
.  ||| S:2621 E:2623 ||| .
In  ||| S:2623 E:2626 ||| IN
nucleoside-naive  ||| S:2626 E:2643 ||| JJ
HBeAg-negative  ||| S:2643 E:2658 ||| JJ
patients  ||| S:2658 E:2667 ||| NNS
the  ||| S:2667 E:2671 ||| DT
probabilities  ||| S:2671 E:2685 ||| NN
were  ||| S:2685 E:2690 ||| VBD
90 ||| S:2690 E:2692 ||| CD
% ||| S:2692 E:2693 ||| NN
,  ||| S:2693 E:2695 ||| ,
100 ||| S:2695 E:2698 ||| CD
%  ||| S:2698 E:2700 ||| NN
and  ||| S:2700 E:2704 ||| CC
96 ||| S:2704 E:2706 ||| CD
%  ||| S:2706 E:2708 ||| NN
respectively ||| S:2708 E:2720 ||| RB
.  ||| S:2720 E:2722 ||| .
The  ||| S:2722 E:2726 ||| DT
manufacturer ||| S:2726 E:2738 ||| NN
's  ||| S:2738 E:2741 ||| POS
lifetime  ||| S:2741 E:2750 ||| NN
treatment  ||| S:2750 E:2760 ||| NN
scenario  ||| S:2760 E:2769 ||| NN
for  ||| S:2769 E:2773 ||| IN
HBeAg-negative  ||| S:2773 E:2788 ||| JJ
patients  ||| S:2788 E:2797 ||| NNS
and  ||| S:2797 E:2801 ||| CC
the  ||| S:2801 E:2805 ||| DT
ERG ||| S:2805 E:2808 ||| NNP
's  ||| S:2808 E:2811 ||| POS
20-year  ||| S:2811 E:2819 ||| JJ
treatment  ||| S:2819 E:2829 ||| NN
scenario  ||| S:2829 E:2838 ||| NN
for  ||| S:2838 E:2842 ||| IN
HBeAg-positive  ||| S:2842 E:2857 ||| JJ
patients  ||| S:2857 E:2866 ||| NNS
increased  ||| S:2866 E:2876 ||| VBD
the  ||| S:2876 E:2880 ||| DT
ICERs ||| S:2880 E:2885 ||| JJ
,  ||| S:2885 E:2887 ||| ,
particularly  ||| S:2887 E:2900 ||| RB
in  ||| S:2900 E:2903 ||| IN
the  ||| S:2903 E:2907 ||| DT
latter  ||| S:2907 E:2914 ||| JJ
case ||| S:2914 E:2918 ||| NN
.  ||| S:2918 E:2920 ||| .
Amending  ||| S:2920 E:2929 ||| VBG
the  ||| S:2929 E:2933 ||| DT
HBeAg-negative  ||| S:2933 E:2948 ||| JJ
model  ||| S:2948 E:2954 ||| NN
so  ||| S:2954 E:2957 ||| RB
that  ||| S:2957 E:2962 ||| IN
patients  ||| S:2962 E:2971 ||| NNS
with  ||| S:2971 E:2976 ||| IN
compensated  ||| S:2976 E:2988 ||| JJ
cirrhosis  ||| S:2988 E:2998 ||| NN
would  ||| S:2998 E:3004 ||| MD
also  ||| S:3004 E:3009 ||| RB
receive  ||| S:3009 E:3017 ||| VB
lifetime  ||| S:3017 E:3026 ||| NN
treatment  ||| S:3026 E:3036 ||| NN
gave  ||| S:3036 E:3041 ||| VBD
probabilities  ||| S:3041 E:3055 ||| VBN
of  ||| S:3055 E:3058 ||| IN
entecavir  ||| S:3058 E:3068 ||| NNS
being  ||| S:3068 E:3074 ||| VBG
cost-effective  ||| S:3074 E:3089 ||| JJ
at  ||| S:3089 E:3092 ||| IN
a  ||| S:3092 E:3094 ||| DT
willingness  ||| S:3094 E:3106 ||| NN
to  ||| S:3106 E:3109 ||| TO
pay  ||| S:3109 E:3113 ||| VB
of  ||| S:3113 E:3116 ||| IN
20,000  ||| S:3116 E:3123 ||| CD
pounds  ||| S:3123 E:3130 ||| NNS
and  ||| S:3130 E:3134 ||| CC
30,000  ||| S:3134 E:3141 ||| CD
pounds  ||| S:3141 E:3148 ||| NNS
of  ||| S:3148 E:3151 ||| IN
4 ||| S:3151 E:3152 ||| CD
%  ||| S:3152 E:3154 ||| NN
and  ||| S:3154 E:3158 ||| CC
40 ||| S:3158 E:3160 ||| CD
%  ||| S:3160 E:3162 ||| NN
respectively ||| S:3162 E:3174 ||| RB
.  ||| S:3174 E:3176 ||| .
The  ||| S:3176 E:3180 ||| DT
NICE  ||| S:3180 E:3185 ||| NNP
guidance  ||| S:3185 E:3194 ||| VBD
issued  ||| S:3194 E:3201 ||| VBN
in  ||| S:3201 E:3204 ||| IN
August  ||| S:3204 E:3211 ||| NNP
2008  ||| S:3211 E:3216 ||| CD
as  ||| S:3216 E:3219 ||| IN
a  ||| S:3219 E:3221 ||| DT
result  ||| S:3221 E:3228 ||| NN
of  ||| S:3228 E:3231 ||| IN
the  ||| S:3231 E:3235 ||| DT
STA  ||| S:3235 E:3239 ||| NNP
states  ||| S:3239 E:3246 ||| NNS
that  ||| S:3246 E:3251 ||| IN
entecavir  ||| S:3251 E:3261 ||| NN
is  ||| S:3261 E:3264 ||| VBZ
recommended  ||| S:3264 E:3276 ||| VBN
as  ||| S:3276 E:3279 ||| IN
an  ||| S:3279 E:3282 ||| DT
option  ||| S:3282 E:3289 ||| NN
for  ||| S:3289 E:3293 ||| IN
the  ||| S:3293 E:3297 ||| DT
treatment  ||| S:3297 E:3307 ||| NN
of  ||| S:3307 E:3310 ||| IN
people  ||| S:3310 E:3317 ||| NNS
with  ||| S:3317 E:3322 ||| IN
chronic  ||| S:3322 E:3330 ||| JJ
HBeAg-positive  ||| S:3330 E:3345 ||| JJ
or  ||| S:3345 E:3348 ||| CC
HBeAg-negative  ||| S:3348 E:3363 ||| JJ
hepatitis  ||| S:3363 E:3373 ||| NN
B  ||| S:3373 E:3375 ||| NN
in  ||| S:3375 E:3378 ||| IN
whom  ||| S:3378 E:3383 ||| WP
antiviral  ||| S:3383 E:3393 ||| JJ
treatment  ||| S:3393 E:3403 ||| NN
is  ||| S:3403 E:3406 ||| VBZ
indicated ||| S:3406 E:3415 ||| VBN
.  ||| S:3415 E:3417 ||| .
